Norgine will market Pedmark, indicated to reduce risk of chemotherapy-related hearing loss in pediatric cancer, in the EU and UK. It will seek additional approvals in Australia and New Zealand.
Who: Fennec Pharmaceuticals/Norgine B.V.
What: Fennec licensed commercial rights to platinum chemotherapy-related hearing loss drug Pedmark in the EU, Australia and New Zealand to Norgine.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.
The Italian drugmaker gets rights to Phase III-ready asset radiprodil.
Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.
The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.
CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.
Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.
A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.
